Laurus Labs Limited vs Sanofi Consumer Healthcare India Limited
A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Sanofi Consumer Healthcare India Limited (SANOFICONR) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Sanofi Consumer Healthcare India Limited leads LAURUSLABS vs SANOFICONR on 8 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability04
- Growth· not comparable—
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
SANOFICONR takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SANOFICONR takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LAURUSLABS takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["Stock is trading at 20.99 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
- + ["Company has been maintaining a healthy dividend payout of 71.9%"]
- − []
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.